PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

(Under the Department of Pharmaceuticals, Govt. of India)

B-500, B-Tower, 5th Floor, Nauroji Nagar, World Trade Center, New Delhi-110029

Amendment No. 1

No: PMBI/DRUG/RC-240/2026. **Dated: 23/11/2026**

Subject: - e-Tender No. PMBI/DRUG/RC-240/2026 dated 31/10/2026 for Supply of 140 Drugs to Pharmaceuticals & Medical Devices Bureau of India (PMBI).

Pharmaceuticals & Medical Devices Bureau of India (PMBI) has invited e-Bids from the interested eligible manufacturers/ parties for "Supply of 140 Drugs for the year 2026-2028", vide Notice Inviting e-Tender No.- PMBI/DRUG/RC-240/2026 dated 03/11/2026. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on Central Public Procurement Portal; www.eprocure.gov.in as well as PMBI Websites; www.janaushadhi.gov.in/ pmbi.co.in.

The following amendment in Tender Document are hereby authorized through Part-A and Part-B: -

Part- A

Sr. No.	Tender Clause/ Reference	Queries/ Suggestions	Clarification/ Amendment
1	Clause 3A(a), 6.A	Representative of the manufacturer has requested for exemption to Micro and Small Enterprises (MSEs) from submission of Earnest Money Deposit (EMD) against the tender.	**No change** Tender condition prevails.
2	Clause 19.O, Para VI of Annexure II	Representative of the manufacturer has requested to accept the DC-1515 & 2073 with shelf-life of 18 months.	**No change** Tender condition prevails. It is Clarified that all the tendered drugs, bidder must comply the shelf life of each quoted drugs in accordance with the "Schedule - P" of Drugs and Cosmetics Rules, 1945. In case drug/medicine not covered in Schedule P of Drugs and Cosmetics Rules, 1945, the bidder must supply the drug/medicine with minimum 24 months shelf life.

3	Clause 3.A.d.vi	Representative of the manufacturer requested for relaxation regarding submission of three-year-old Market Standing Certificate for invited drug codes DC-2312 and DC-2516, stating that the patent for both drugs expired in March 2025.	**No change** Tender condition prevails. It is Clarified that as per clause 3.A.d.vi for the drugs, where patent has recently been expired (in 2024-2026) submission of market Standing Certificate may be exempted. However. if the patent is expired before FY 2023-24, bid of such drugs may be accepted with two-year Market Standing Certificate.

Part – B

The following Amendments in detailed Specification/Packaging/Unit Size are hereby authorized: -

Sl. No	Tender Clause/ Reference	Drug Code	Generic Name of the Drug	Detailed Specification	Unit Size	Bidders Query	Clarification/ Amendment
1	Annexure - XII Clause 18 (A)	834	Cholecalciferol (Vitamin D3)Drops 400 IU per ml	Each ml contains: Vitamin D3 IP 400IU (Cholecalciferol)	15ml	Bidder has requested for amendment in the detailed specification of DC-834 as Each 0.5ml contains: Vitamin D3 IP 400IU (Cholecalciferol).	**No change** *Tender condition prevails.*
2	Annexure - XII Clause 18 (A)	1707	Metoprolol Succinate Extended-Release Capsules 50mg	Each Hard Gelatin Capsule contains: Metoprolol Succinate IP Equivalent to Metoprolol Tartrate 50mg	10's	Bidder has requested for amendment in the generic name and its detailed specification of DC-1707 as **Metoprolol Succinate 50 mg Tablet** Each uncoated Tablet contains: Metoprolol Succinate IP Equivalent to Metoprolol Tartrate 50mg.	**No change** *Tender condition prevails*
3	Annexure - XII Clause 18 (A)	1708	Metoprolol Succinate Prolonged Release Tablets IP 25mg	Each Film Coated Prolonged Release Tablet contains: Metoprolol Succinate IP equivalent to Metoprolol tartrate 25mg	15's	Bidder has requested for amendment in the generic name and its detailed specification of DC-1708 as **Metoprolol Succinate Tablets IP 25mg** Each uncoated tablet contains Metoprolol	**No change** *Tender condition prevails*

						Succinate IP equivalent to Metoprolol tartrate 25mg.	
4	Annexure - XII Clause 18 (A)	1755	Paracetamol Suspension IP 120mg	Each 5ml contains: Paracetamol IP 120mg	60ml	Bidder has requested for amendment in the generic name and its detailed specification of DC-1755 as **Paracetamol Oral Suspension IP 125 mg** Each 5 ml contains: Paracetamol IP 125 mg.	**<u>No change</u>** *Tender condition prevails*
5	Annexure - XII Clause 18 (A)	2630	Sildenafil Tablets 20mg	Each film coated Tablet contains: Sildenafil Citrate IP equivalent to sildenafil 20mg	10's	Bidder has requested for amendment in the generic name and its detailed specification of DC-2630 as **Sildenafil Tablets 25 mg** Each uncoated Tablet contains: Sildenafil Citrate IP equivalent to sildenafil 25mg.	**<u>No change</u>** *Tender condition prevails*

All other contents of tender document remain unaltered. Bidders are requested to quote their rates considering all the terms and condition of the tender document including this Amendment No. 1 dated 23/11/2026.

Sd/-
Chief Executive Officer,
Pharmaceuticals & Medical Devices Bureau of India